International Journal of Biological and Pharmaceutical Sciences Archive

ISSN: 0799-6616 (Online)

Journal homepage: https://ijbpsa.com/

(REVIEW ARTICLE)

Check for updates

REGULATORY PERSPECTIVE AND CHALLENGES OF ADVANCED NOSE – TO- BRAIN DRUG DELIVERY SYSTEMS IN CNS THERAPEUTICS

Jadhav Pratiksha Sanjay [1,*], Khope Sanjana Shrikrishna [1], Khan Mntasha Naushad [1], Jadhav Sanjana Jaywant [1], Shelake Poonam Shantaram [1] and Khairnar Rohit Ramdas [2]

[1] Research Scholar, Siddhis Institute of Pharmacy Nandgaon, Murbad 421401.
[2] Assistant professor, Department of Pharmacology, Siddhis Institute of Pharmacy Nandgaon, Murbad 421401.
* Corresponding Author

International Journal of Biological and Pharmaceutical Sciences Archive, 2026, 12(02), 104–119

Publication history: Received on 19 September 2026; revised on 29 October 2026; accepted on 02 November 2026

Article DOI: https://doi.org/10.53771/ijbpsa.2026.12.2.0105

Copyright © 2026 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0

ABSTRACT

The central nervous system (CNS) which includes the brain and spinal cord controls vital functions of the human body. Treating CNS disorders is still hard because the blood–brain barrier (BBB) blocks medicines from reaching the brain. Conventional ways to give medicine, such as pills or injections often fail to deliver drug to the right spot. That is why nose-to-brain drug delivery has become a non-invasive way to bring medicines straight to the CNS.

The close anatomical and physiological connections between the nose and the brain through the olfactory and trigeminal nerves allow the drug to reach the CNS directly and reduce dependence on the bloodstream. This approach can also avoid first-pass liver metabolism. May make treatment easier for patients. New formulations like nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers and nano emulsions are being studied to improve drug stability, nasal absorption and CNS targeting.

These advances face many obstacles: the nose's mucociliary clearance, limited drug spread difficulty proving direct nose-to-brain movement, identifying nanocarrier properties, standardizing formulations, batch variation and checking long-term safety. From a point of view a detailed evaluation of quality, safety and effectiveness is essential. Key elements such as quality features, analytical tests, stability studies, manufacturing control, validated preclinical models, pharmacokinetic and pharmacodynamic data and appropriate clinical trials are needed for product development. Harmonized regulations and consistent testing methods are also critical to bring these formulations into clinical use.

Keywords: Nasal-, To-Brain Drug Delivery; Nervous System (CNS); Blood-Brain Barrier (BBB); Tiny Delivery Vehicles; Intranasal Drug Delivery.

1 INTRODUCTION

1.1 Central Nervous System (CNS) And CNS Disorders

The central nervous system (CNS) is an important part of the nervous system. It includes the brain and spinal cord. It is connected to many important functions in the body. A problem with the nervous system can be defined as a condition

that affects either the spinal cord (called myelopathy) or the brain (called encephalopathy) or both. The causes of CNS problems include things, such as unusual body structures, infections, injuries, issues, with the immune system cancers, diseases that damage nerves and other factors. These causes can lead to disorders, neuropsychiatric disorders, neurodegenerative disorders or neurodevelopmental disorders.[1]

1.2 Challenges In Conventional CNS Drug Deliver

Brain barriers, such as the blood-brain barrier (BBB) the blood-cerebrospinal fluid barrier and the blood Tumer barrier help protect the brain from substances. These barriers limit the movement of chemicals into the brain and help keep the brain environment stable. The blood-brain barrier is made up of cells that line the small blood vessels. These cells are supported by cells around them like astrocytes, pericytes and microglia which connect tightly to form tight junctions These tight junctions create a barrier giving the BBB high electrical resistance compared to other parts of the body. Because of these small molecules with molecular weight and those that are not polar pass through more easily than large or polar molecules, such, as proteins and peptides.[2]

Under physiological conditions circulating molecules can only reach the brain or cerebrospinal fluid by moving through capillary endothelial cells or choroid plexus cells. This movement occurs by either transport or active transport or sometimes by both. [3]The main passive route is diffusion. In general only lipid-soluble molecules that weigh less than about 400–600 daltons can cross the cells that are joined by TJs. Receptor-mediated transport helps macromolecules that are linked to surface receptor ligands move across. Examples of ligands are transferrin, lactoferrin and insulin. Absorptive-mediated transport is a type of endocytosis that is triggered by substances that carry actionized ligands or peptides such, as albumin.[3]

Because the blood-brain barrier has a protein called P-glycoprotein also known as the multidrug resistance associated membrane protein drugs can be pushed back into the blood by pumps that use ATP. However while the blood-brain barrier protects the brain it also blocks than 98% of small-molecule drugs and all large-molecule treatments from reaching the brain. The small spaces in the blood-brain barrier let lipid-soluble drugs that weigh less than, about 400-600 daltons slip through by passive diffusion. Making therapeutic agents more lipophilic is a way to help them cross the blood-brain barrier. For example Crizotinib is a small-molecule tyrosine-kinase inhibitor that you can take by mouth and that works well against cancers but it does not fight brain tumour spread effectively because it does not cross the blood-brain barrier easily .[4]

1.3 Need For Alternative CNS Drug Delivery Approaches .

The CNS is strongly protected by physiological barriers , especially the blood–brain barrier and the blood–cerebrospinal fluid barrier, which keep most drugs out. Scientists can create biomaterials that slip past or go through these walls so that drugs can be released in a controlled way inside the CNS. Next we talk about CNS drug delivery plans and the materials that are given either through the bloodstream directly into the CNS through the nose or, by injecting into muscles.[5]

1.4 Emergence Of Nose To Brain Drug Delivery

Neurological disorders remain the cause of disability across the globe and they place a heavy load on our healthcare system . Delivering medicines to the brain is tough because the Blood Brain Barrier (BBB) stops drugs the brain is very intricate and the risks of safety and toxicity are high . I find nose-to-brain delivery it is a new non-invasive way that can beat traditional systemic drug use. It may reduce systemic toxicities produce fewer side effects stay non-invasive act quickly and raise the amount of medicine reaching the Central Nervous System (CNS) . This route cuts across the BBB by using the neural links that run through the olfactory epithelium, olfactory bulb, trigeminal nerve and the brain itself.

The nasal cavity is split in two by the nasal septum and each side holds three areas: the nasal vestibule, the respiratory region and the olfactory region. The nasal vestibule is the nose's door; it has a squamous lining, tiny hairs (vibrissae) and oil-producing sebaceous gland. It is lined with pseudostratified epithelium (olfactory epithelium) and holds the olfactory nerve that gives medicine direct access, to the CNS while bypassing the BBB.[6]

1.5 Why Regulatory Perspective is Important

While there are approved drug formulations for local and systemic uses creating nasal drug formulations for CNS delivery remains difficult. This review paper explains the possibilities and benefits of drug delivery and it also points out the current limits and toxicological concerns. The future directions for developing drugs for local, systemic and CNS uses are highlighted. Getting approval for a candidate to reach the market is the final step in a long drug development process but the regulatory issues must be considered from the start. To receive approval of any drug product in the USA the product must meet safety, efficacy and quality requirements. The same safety, efficacy and quality requirements apply to biologics well as to small-molecule drugs. Chemistry, manufacturing and controls are critical, for ensuring the quality and consistency of nose-to-brain formulations. Quality control, product characterization, critical quality

attributes and manufacturing processes must all be evaluated carefully. The nasal delivery device must also be assessed to ensure it delivers the drug reliably.[7]

2 CNS DISORDERS AND CHALLENGES IN CNS DRUG DELIVERY

2.1 Overview Of CNS Disorders

The central nervous system is a part of our body. The central nervous system consists of the brain and the spinal cord and the central nervous system links, to important functions of the body. When the central nervous system has a problem the central nervous system is called a nervous system disorder and the central nervous system disorder can affect the spinal cord a condition called myelopathy or it can affect the brain.[8]

2.2 Major Therapeutic Targets In CNS Disorders

- Alzheimer's disease involves problems with neurotransmission, the tau protein and amyloid-beta (Aβ).
- Parkinson's disease features dysfunction and disrupted dopamine signalling.
- Epilepsy involves imbalances, in GABA neurotransmission and glutamate neurotransmission.
- Depression involves the neurotransmission of noradrenaline. Serotonin.[9]

2.3 Limitations of Conventional CNS Drug Delivery

Brain cancer is hard to treat in ways because the BBB stops drug delivery from reaching the tumour. The changes that happen with Brain cancer can block drug delivery. The changes that happen with Brain cancer can also be used to help drug delivery.

Efflux transporters work like pumps in the brain. They push drugs back into the blood. This means less medicine stays in the brain tissue where it's needed. Even if a drug gets past the blood-brain barrier it still might not reach the place, in the brain. Getting through brain tissue is tough. That's why making drugs for the nervous system is so hard. It costs a lot of money. It takes a time.. Many drugs don't work in the end. Systemic drug administration can lead to the drug reaching organs and tissues that do not need it. This can result in side effects that are not wanted. It may also cause toxicity, in areas of the body that were not meant to be affected.[10]

2.4 Physiological Barriers to CNS Drug Delivery

Drug delivery challenges to the brain are often because of the tightly controlled barriers that stop a drug from getting to where it needs to go in the brain after it enters the brain after Specifically two barrier sites between blood and the brain after it enters the body .These are the blood-brain barrier and the blood-cerebrospinal fluid barrier. Also no matter how the drug is given to the brain the drug delivery systems need to move into the brain tissue to get to the areas where the disease's. Tight junctions between brain blood vessel cells control how things move between the cells. Carbohydrates, acids and hormones must pass through the blood-brain barrier using special transporters in the blood vessel cells. Also efflux mechanisms using ATP-binding cassette transporters push drugs, drug combinations, foreign substances and natural chemicals back into the blood. This helps keep the barrier, between the blood and the brain working .

2.5 Challenges in Achieving Therapeutic Drug Concentration in the Brain

If treatments can get past the blood-brain barrier or the blood-cerebrospinal fluid barrier. If they are given directly to the brain to skip these barriers there is still the problem of moving through the brain tissue from where the drug enters to the cells or areas that need treatment.[10]

I see that successful neuropharmacology depends on optimization of CNS drug delivery and as a result on free drug concentrations at brain molecular targets. The next frontier in CNS drug delivery is targeting BBB uptake transporters. This approach requires evaluation of brain endothelial cell transport processes so that drugs can accumulate effectively and therapeutic efficacy can improve. BBB permeability of drugs is controlled by tight junction protein complexes, which act as a barrier and, by transporters and enzymes which act as a biochemical barrier.[11]

We then perform an analysis of the current state-of-the-art approaches that have been developed to overcome these barriers and to achieve precision targeting at different levels.

3 NOSE-TO-BRAIN DRUG DELIVERY: CONCEPT AND BASIS

The blood–brain barrier is an obstacle for treating central nervous system disorders because it stops most therapeutic agents from reaching the brain after oral or parenteral administration. Lately intranasal administration of drugs has

become more popular because it can bypass the blood–brain barrier. This route is suitable, for application and allows therapeutic molecules to be transported directly into the brain bypassing the blood–brain barrier and increasing drug concentrations in the central nervous system.[13]

3.1 Concept Of Nose -To – Brain Drug Delivery Systems

Treatment of nervous system diseases is very difficult because the blood-brain barrier can stop most substances from entering the brain. Only small and non-polar substances can pass through the blood-brain barrier easily. Intranasal delivery of molecular weight biologics such as proteins, gene vectors and stem cells is a strategy that could be very useful, for treating different diseases and disorders of the central nervous system. These include stroke, Parkinsons disease, multiple sclerosis, Alzheimers disease, epilepsy and psychiatric disorders. Here we give an overview of the nasal anatomy and physiology that's relevant. We also discuss the pathways and the mechanisms that are likely involved in moving drugs from the nasal lining to the nervous system.[12]

3.2 Basis and Mechanism of Nose-to-Brain Drug Delivery

The nose area of people and other animals like mice and rats is split into two parts by the nose wall. The two nose holes make the start of the nose area which connects to the inside of the nose. Inside the nose there are three nose parts which create the nose passages . The whole nose area except the nose area near the nose holes is covered with nose tissue which can be split into the breathing part and the smelling part Nose to brain drug delivery is a way to get past the blood brain wall. Signs of a link between the nose and the brain were found at the start of the last century as scientists showed that things put into the space around the brain can get to the nose tissue This idea comes from studies that found lots of drugs in the side smell area the smell ball and the face area after putting them in the nose proof of the smell path came almost 100 years ago when scientists thought that viruses move from the smell area of the nose along the smell nerve to the brain The face path includes moving along different parts of the face nerve that control the nose breathing area: the bone part coming from the eye nerve as well as the back nose parts and the nose mouth part coming from the upper jaw nerve . They go to the face ball and the face areas in the brain stem Things are probably moved outside the cells through smell lymph, around blood vessels and around nerves, to the brain fluid . This path is seen as a move as models of how long it takes different paths to reach the smell ball show that only big flow moves are fast enough to explain what was seen in experiments. Cellular processes such as endocytosis help transport work. These cellular processes let olfactory sensory neurons soak up drug molecules. The drug molecules can then travel to the olfactory bulb by transport, along olfactory nerve fibers. This gives a route into the central nervous system [13]

3.3 Possible routes from nose to brain

3.3.1 Olfactory route

The olfactory region is found at the top of the dorsal meatus. Is made up of olfactory mucosa. Thin nerve fibers, called fila olfactoria supply this area. These fibers come from the olfactory nerve, which carries signals from the olfactory bulb through the lamina cribrosa to the olfactory region (Fig. 1A). This means the olfactory nerve creates a link between the brain and the nose. Because of this connection delivery from the nose to the brain can be more efficient through the olfactory mucosa than, through the respiratory mucosa.

3.3.2 Trigeminal route

was intrigued to learn that the ophthalmic and maxillary nerve branches of the nerve can reach epithelial cells in the olfactory and respiratory areas of the nasal cavity. Meanwhile the other end of nerve branches goes into the CNS at the pons and ends at the spinal nucleus of the trigeminal nerve in the brainstem. The concentration in the nerve was ten times higher than in the olfactory bulb confirming that the trigeminal nerve can act as a route, for drugs to reach the brain after intranasal administration.[14]




Figure 1: Schematic representation of the olfactory and trigeminal pathways involved in nose-to-brain drug delivery.

3.4 Limitations of Conventional Nasal Delivery

The amount of medicine that can be given is limited to 25–200 µL. It can be hard to deliver drugs that're large in size like high-molecular-weight APIs. The nose has systems, such as mucociliary clearance, which might stop the drug from being absorbed properly. There are enzymes, in the nasal area that could break down some APIs before they work. Sometimes the medicine can cause side effects like irritating the mucous membrane.

If someone has a cold and their nose is stuffy that can get in the way of the API being delivered properly.[15]

4 ADVANCED NOSE-TO-BRAIN DRUG DELIVERY SYSTEMS

The nasal route offers an alternative, to oral and/or parenteral administration. The nasal route provides a way to achieve nose-to-brain drug delivery that uses the olfactory and trigeminal nerves and it helps local or systemic drug action. Conventional liquid nasal dosage forms have not bridged the gaps of dosing or targeted central nervous system delivery. Sophisticated formulation approaches are being explored for brain targeting aiming to increase bioavailability and therapeutic efficacy. The nasal route and nose-to-brain drug delivery rely on the olfactory and trigeminal nerves to reach the brain and to improve drug action. [16]

4.1 Nanoparticle-based systems

Nanotechnology has made a difference in pharmaceutical sciences especially in making tiny drug delivery systems over the last few decades. These tiny systems are usually made of particles than 1000 nm. They come with advantages. For example they have a surface area, which helps drugs dissolve better get absorbed more easily and stay stable for longer. Common types of nanocarriers used to carry drugs include micelles, liposomes, nanoemulsions, polymeric nanoparticles (NPs) solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). These systems are being used often for nose-, to-brain drug delivery. That's because they can help get around some of the problems that come with intranasal (IN) administration. [17]




Figure 2: Types of Nanoparticle-Based Systems Used for Nose-to-Brain Drug Delivery

4.2 Nano emulsions




Figure 3: Schematic Representation of Nanoemulsions for Nose-to-Brain Drug Delivery: Types, Composition, Preparation Methods, Advantages and Limitations

Nano emulsions (NEs) are oil-in-water (O/W). Water-in-oil (W/O) mixtures of two liquids that do not blend together. Nano emulsions use surfactant(s) to keep the two liquids mixed. The average diameter of the droplets in nano emulsions is around 100 nanometres although some studies report droplets up to 300 nanometres. Because the droplets are much smaller than the wavelength of light Nano emulsions are usually clear or sometimes look milky white. Nano emulsions can be made into types of dosage forms, such as liquids, creams, gels, foams and sprays. Nano emulsions can be given through routes: oral, parenteral, ocular and nasal. The amount of component in Nano emulsions depends on the type of emulsion. In oil-in-water Nano emulsions 5 to 20 percent of the mixture is lipidic droplets. The amount of component also depends on how well the drug can dissolve in the system. The oil phase must be able to dissolve the drug and keep it dissolved. Therefore the solubilizing capacity of the oil phase is a factor when choosing the oil, for Nanoemulsions.[18]

4.3 Liposomes

Liposomes are spherical structures made up of one or more phospholipid bilayers. They look like the natural membranes found in our cells [129]. Because of this structure liposomes can hold kinds of drugs. Water-loving drugs fit inside the water-filled space while fat-loving drugs get trapped in the lipid layers themselves. One important use is in nose-, to-brain delivery. The liposomes can travel from the nose through the nasal passages. Cross into the brain. This method is being used more and more to treat brain diseases because it avoids the blood-brain barrier and delivers drugs directly where they are needed. [19]




Figure 4: Schematic Representation of Liposomes and Their Role in Nose-to-Brain Drug Delivery.

4.4 Nanogel

Nanogels have appeared as a promising way to deliver drugs because of their strong ability to stay stable in liquid form their ability to hold a lot of medicine their structure that has a core and a shell their good ability to move through tissues and their ability to react to changes in the environment. These tiny drug carriers have better abilities than regular nanomaterials when it comes to moving into the brain tissue in lab tests and in living beingsNanogel-based systems can be designed to go past the bodys barriers without needing surgery making it one of the best options for dealing with brain-related problems like diseases that make the brain break down brain.[20]

5 FORMULATION AND PHARMACEUTICALS CONSIDERATION

This method of administration has been used well to carry a medicine to places inside the brain. Clinical work has been done by putting a drug solution into the cavity because delivering medicine to the brain works better through this pathway than by mouth or IV. Nasal sprays are the way to give intranasal solutions. Drops can also be used,. They are not as good because they leave the nasal cavity faster than sprays (Hardy et al. 1985). Different strategies, like nasal solutions, mucoadhesive systems, gels and nanocarrier based formulations have been tried to keep the drug in the body and help it move to the brain.

In product development things like PH , Viscosity, drug stability and how well excipients work together need to be through . Mucoadhesive and it situ gelling system can help a formulation stay in nasal cavity Longer reduce How fast it gets clear out by mucociliary system picking the nasel delivery device Is important To because It affects Where the drug

goes and how will it work . To make sure the final product is safe , effective and stay consistent These factor should be carefully adjusted.[21]

6 QUALITY AND CRITICAL QUALITY ATTRIBUTES OF NOSE TO BRAIN SYSTEM

6.1 Critical Quality Attributes (CQAs)

Critical Quality Attributes are the physical and chemical traits of Formulations that help keep it high in quality, safe and effective. In nose – to -brain drug delivery people check Critical quality attributes to make sure the formulations is even and that the drug reaches the brain reliably. The assessment of Critical quality attributes is key, to drug delivery.[22]

6.1.1 Particle size:

Particle size matters a lot because it can influence how the drug is released how stable the formulation is and how well the drug works when given through the nose. It is usually checked using particle size analysis techniques.

6.1.2 Polydispersity Index (PDI)

PDI shows how spread out the particle sizes are in a nanoparticle mix. When the PDI is lower it means the particles are more similar in size. This makes the formulation more uniform. A smaller PDI is often better for stability and performance. It's a number that tells a lot, about the quality of the nanoparticles.

6.1.3 Zeta Potential

Zeta potential denotes the charge related to the surface of nanoparticles. Zeta potential can assist in evaluating particle interactions and the physical stability of a formulation.

6.1.4 Drug Content

Medication content means how much of the drug is actually, in a medicine product. It is checked using a lab method to find out the drug amount and how evenly it is spread in the product. This helps make sure every dose has the amount of medicine.[24]

6.1.5 Encapsulation Efficiency (EE%)

Encapsulation efficiency shows how much of the drug is actually held inside the nanocarrier during the preparation. This measure helps in understanding how well the delivery system can hold the drug.

6.1.6 pH:

The pH of a nasal product must be checked to make sure it is safe for nasal use and matches, with the nasal lining. A correct pH helps prevent irritation. Ensures the product works properly in the nose.

6.2 Analytical Characterization:

Analytical characterization is very important to assess the quality and efficacy of nose-to-brain drug delivery systems. Analytical characterization includes the application of analytical methods to evaluate drug release, spray attributes, nasal deposition and other formulation-related characteristics.

6.2.1 Drug Release

I think drug release is very important to evaluate the drug release profile from the formulation under defined settings.

6.2.2 Droplet. Spray Attributes

I think droplet size, plume shape and spray pattern are crucial to understand spray performance and the likely spread of the formulation, within the nasal cavity .

6.3 In -Vitro Drug Release

In vitro methods were created to replace in vivo and ex vivo methods. A variety of cell models are available to study drug delivery. These cell models include cell lines and immortalized cell cultures. Their aim is to mimic the human nasal mucosa and should cover all properties that may affect the drug pharmacokinetics after intranasal administration. Cell models can be used to study the membrane permeability of drug molecules or colloidal carriers. Cell models offer control of the culture conditions—growth and differentiation of epithelial cells or high-throughput screening.[25]

6.4 Ex -Vivo permeation Studies

In science ex vivo means scientists do experiments or take measurements on tissues from an organism outside the body while trying to keep the environment close to natural as possible. Ex vivo tissue-based models have been created as a replacement for, in vivo and cell-based models. Ex vivo models help scientists study how drugs move through the nose, how the body breaks them down how the drugs leave the body and how dangerous they might be. Ex vivo models however do not last long and their health can be hurt by poor storage conditions.[25]

6.5 In -vivo Biodistribution Studies

In-vivo research is done to see what happens when medicines are given through the nose. These studies help look at how the body handles the medicine how it works and if it is safe when delivered through the nose to the brain. Picking the animal to use is very important because the nose structure and how it works can change how the medicine is absorbed and moves. In-vivo studies can also help check if a medicine works before going with development. However using animals in research has problems like costs ethical concerns and differences, between animals and people.

6.6 Batch To Batch Consistency

Consistency between batches is a part of quality control in nose-to-brain drug delivery systems. It means that every batch of the product should have the quality, the same physical and chemical properties and should work in the same way. Small changes in the materials in how the formula's prepared or in the conditions during manufacturing can affect quality features. These features include particle size, polydispersity index, zeta potential and how well the drug is held inside the formulation. Because of this product requires that the manufacturing steps be controlled and the quality traits be monitored. As production moves from lab batches, to industrial scale keeping the product the same becomes much more difficult. Using Good Manufacturing Practices and strong quality management systems helps make the process repeatable. This ensures the final product is reliable and safe.[28]

7 SAFETY AND TOXICOLOGICAL CONSIDERATIONS

7.1 Nasal Mucosal Toxicity

Nasal mucosa is the tissue that comes into contact with any formulation given through the nose. The safety of nose-, to-brain drug delivery systems depends on how the drug, the excipients and the overall formulation affect the nasal tissue. Absorption enhancers are used to help the drug pass through the tissue easily. Mucoadhesive substances are added to keep the formulation in place longer by sticking to the nasal mucosa.. If the formulation stays in the nose for too long or if the wrong excipients are used it could harm the local tissue. That’s why it is important to check the health of the nasal mucosa and how well the tissue tolerates the formulation during development. This evaluation helps ensure that the treatment is both effective and safe. [26]

7.2 Ciliotoxicity

The nose has hair-like cells called ciliated epithelial cells. These cells help get rid of mucus and other stuff by moving it out. The way a product is made like the pH and how salt it has can affect how these cells work. Some ingredients, like benzalkonium chloride and certain other chemicals can slow down the movement of the cilia. This happens depending on how much of the ingredient is there and how long it stays in the nose. When the cilia don't work well the nose can't clean itself properly. Because of this the speed of the cilia and the way they move mucus must be considered when checking if a nasal product is safe.

7.3 Local Irritation

Local irritation is a problem when giving medicine through the nose. Local irritation can be caused by the pH, the concentration of the solution the preservatives used and the substances that help the medicine get through the nose. In water-based medicines the preservatives can make the nose feel irritated. The preservatives can cause a reaction. The substances that help the medicine get in can change the mucus. The substances that help the medicine get in change how the skin in the nose lets things through. Possible effects, on the nose might include dryness, an itchy feeling, sneezing, irritation and stuffiness. The way the medicine is made and how long it stays in the nose should be considered when looking at the safety.

7.4 Neurotoxicity

Nose-to-brain drug administration is a method used to send medicine to the nervous system through the nose. This happens using the olfactory and trigeminal pathways. When checking if a drug is safe people must look at more than the active part of the medicine. They also need to consider the formula, including all the extra ingredients. The review says it is important to check for any effects on the nose, the body and the brain when making medicines that go into the nose.

Because of this good research, before testing on people is needed to make sure the medicines that go directly to the brain are safe.[27]

7.5 Systemic Toxicity

While putting medicine through the nose might lower how much gets into the body some of the medicine can still get into the bloodstream through the nose lining. The side effects that affect the body depend on the medicine how much is used how it is absorbed and what the medicine does in the body. The review for example talks about side effects that happen when medicines, like diazepam, midazolam and oxymetazoline are given through the nose. Because of this the amount of medicine that gets into the body and the bad effects must be checked along with the plan to send the medicine from the nose to the brain.

7.6 Immunogenicity and Inflammatory Responses

The nasal mucosa acts like a shield. It stops dust, bacteria and other harmful stuff from getting into the body. The things inside nasal sprays or gels can change how the mucus layer on the nasal mucosa works. This mucus layer is very important for protecting the nose. If the mucus layer changes, the nasal lining. Also called the epithelium. Might let harmful things pass through. That can make the nose more sensitive. The area might not handle the product well. Some ingredients, like preservatives can cause irritation or allergic reactions. Because of this every nasal spray or gel must be checked for signs of inflammation, reactions or other bad effects.

8 REGULATORY LANDSCAPE OF NOSE -TO -BRAIN DRUG DELIVERY

Nose-to-brain drug delivery is a way to give medicine to the brain through the nose. When regulators look at these products, they check the quality of the product its safety how well it works and how the delivery device performs. Traditional nasal products are covered by existing rules. Special nose-to-brain drug delivery products may need extra scientific evidence to prove that they deliver medicine effectively and give treatment benefits. Therefore, regulators must consider both the traits of the nose-, to-brain drug delivery formulation and how it will be used in clinical practice.[29] [30]

8.1 Regulatory Classification of Nasal CNS Production

Intranasal formulations can be used for treatment for the whole body or for delivering medicine to the brain. Intranasal formulations must go through an evaluation that looks at the main ingredient the dosage form, the planned use and how the medicine is delivered. New Intranasal formulations may need evidence to show their quality, safety and effectiveness. Therefore, the regulatory route, for each Intranasal formulation should be set by looking at the features of that Intranasal formulation and the rules of the country.[29][30]

8.2 Regulatory Expectations for Novel Drug Delivery system

Advanced nasal formulations, such, as microemulsions, in-situ gels, nasal powders and nanocarriers need pharmaceutical evaluation and performance analysis. Key factors include drug release, formulation stability, nasal absorption, mucosal compatibility and consistency. I believe that preclinical and clinical studies must show that nasal formulations work as intended and offer a therapeutic benefit.[29][30]

8.3 US FDA perspective

The Food and Drug Administration in the United States checks medicines to make sure they meet the rules, for quality, safety and how well they work. When making medicines developers need to set quality features control how they are made and decide how long they stay good. For medicines that go from the nose to the brain the people who make them have to give proof that fits the way the medicine is made and the health problem it is meant to treat. The ICH quality rules apply to making medicines and handling quality by looking at the risks involved.[29][30]

8.4 EMA perspective

The European Medicines Agency (EMA) provides regulatory guidance for making medicines. Important things to consider are how the medicine is made, managing risks related to quality testing how stable it is and controlling how it is produced. For nasal products these general rules need to be used along with specific information, about how safe it is how well it works and how well it delivers the medicine.[29][30]

8.5 CDSCO /INDIA Regulatory Perspectives

The body that regulates medicines, in India is the Central Drugs Standard Control Organization or CDSCO. People who make CNS products must understand and follow Indian rules about getting drug approval doing clinical trials making medicines and keeping product quality high. What the product can do and how it is meant to be used decide the way to

go about it. So at every step of drug approval, clinical trials, production and product quality developers must check the CDSCO rules and guidelines.[31]

8.6 ICH Guidelines Relevant Development

8.6.1 Quality

Pharmaceutical development must clearly define the link between formulation traits, production methods and product efficacy. In my experience pharmaceutical development benefits from quality risk management and quality risk management helps us spot and handle risks that could hurt product quality. A quality system, in pharmaceuticals helps us keep quality steady during development and production and a quality system also supports monitoring.[32]

Guideline

- ICH Q8 (R2). Pharmaceutical Development
- ICH Q9 (R1). Quality risk management
- ICH Q10. Pharmaceutical Quality system

8.6.2 Safety

Non-clinical safety research provides data to help make sure drugs can move safely into human clinical testing. When it comes to CNS formulations safety evaluations must consider how well the product is tolerated in the nose. This includes looking at effects, on the nervous system and other parts of the body. The kind and amount of testing needed depend on what the product's made of and what it is meant to do.[32]

Guidelines

- ICH M3 (R2) :non -clinical safety studies
- ICH S2 (R2) :Genotoxicity
- ICH S4 : Duration of chronic toxicity testing in animal

8.6.3 Stability

I use stability studies to see how the quality of a drug substance or final product changes when it is exposed to environmental factors. The results confirm that the chosen storage conditions, packaging and suggested shelf life are right. For nasal formulations I make sure that important formulation and delivery-system characteristics are carefully monitored during the stability evaluation.[32]

Guidelines

- ICH Q1A(R2):Stability Testing of New Drug Substances and Products.
- ICH Q1B : Photostability Testing of New Drug Substances and Products
- ICH Q1 E : Evaluation of stability data

8.6.4 Clinical development

Clinical development demands trials that're well organized so we can check the safety and effectiveness of a medicinal product. Throughout trials we must think about the study's goals, the endpoints the safety of participants and the integrity of the data. Good Clinical Practice gives rules, for running trials in a way that is ethical and reliable.[32]

Guidelines

- ICH E8(R1). General Considerations for Clinical Studies
- ICH E6(R3). Good Clinical Practice
- ICH E8(R1) – General Considerations, for Clinical Studies

8.7 Regulatory considerations for nanotechnology-Based system

Formulations based on nanocarriers require measurement of features such as particle size, size distribution, shape, surface traits, drug loading and stability all of which matter, for the final product. It is very important that the manufacturing process can be repeated consistently and that different batches stay the same. The product quality remains uniform. Safety assessment must also consider the carrier materials, any added excipients, the products that may form and possible local or overall body effects.[30][33]

8.8 Regulatory considerations for Novel Excipients

We need to test excipients to see if they mix well with the active ingredient and other parts of the formulation. The new excipients must be checked for compatibility, with the ingredient and other elements of the formulation. The way the medication will be given must explain why the excipients are used. It must also show how much of each excipient is used. The purpose of each excipient must be clear. The stability of each excipient must be proven. Finally the safety of each excipient must be confirmed.

8.9 Drug device combinations considerations

The way the medicine is delivered through the nose can change how evenly the dose is given and where the medicine ends up in the nose. For a delivery system important things to look at might include how consistent the dose is, how the spray spreads, the size of the drops and how well the device works with the medicine. These features of the nasal delivery system need to be checked to make sure the product works the way every time.[29][30]

9 LACK OF HARMONIZATION REGULATORY FRAMEWORK

Regulatory rules for nose-to-brain drug delivery systems can be different in various countries, which makes it harder to develop and get approval for these products. The existing guidelines are about the quality and safety of products and drug products that use nanomaterials. More scientific proof might be needed to show that these drugs can deliver medicine effectively to the nervous system. Having ways to study, test, for safety and perform clinical tests could help make regulatory decisions more consisten . [34][35]]

9.1 Complexity of Nanocarrier Characterization

The complexity of evaluating nanocarriers makes it challenging to understand their performance. This is because the quality of these nanocarriers depends on different physical and chemical properties. These properties include the size of the particles how evenly sized they're their shape the electric charge, on their surface how much medicine they can hold and how they release that medicine. To learn about these features the right testing methods are needed. These methods help check how each feature affects the quality, safety and effectiveness of the product. Identifying the important quality features is therefore a key part of making progress in nanomedicine.[34][35]

9.2 Standardization challenges

Standardization is very important for making sure that progressive nose-to-brain formulations have the quality and work the same way. Things like how much drug is in the product the size of the particles how well the drug is wrapped up how it comes out in tests how it lands in the nose and how much gets delivered must be checked using the same methods. If the ways of testing and the rules, for accepting results are different it becomes hard to compare results from studies and make reliable product rules.[34][35]

9.3 Batch -to -Batch Variability

The differences between batches create a problem when making formulations that use nanocarriers. Changes in the materials how the formulation is made and the conditions during processing can change the particles how much drug is included, how it is released and how stable the product is. These changes can make the product not the same each time. Can lower how well it works. So having a controlled way to make the product good checks during the process and tests that work well are very important, for making sure the quality is always the same.[34][35]

9.4 Novel Excipients and insufficient safety Data

Advanced nose-to-brain formulations can include polymers, lipids, nanomaterials or permeation enhancers that need thorough safety checks. The impact on the mucosal lining local irritation, ciliary movement and how much gets into the body should all be taken into account. Giving the formulation times might also mean checking for local safety and possible effects, on the central nervous system depending on what the formulation is and how long it is used. The safety of the formulation must be tested, not just the safety of the active ingredient.[26][35]

9.5 Regulatory Documentation and Data Requirements

Regulatory submissions for pharmaceutical products need enough details about the formulation makeup, how it's made quality assurance steps, testing methods and stability data. For nose-, to-brain delivery systems extra information may be needed. This includes describing the nanomaterials used, identifying quality features checking how well the device works and proving safety and clinical effectiveness. The documents should clearly explain how the production process and quality control methods ensure the product always performs the way.[34][35]

9.6 Clinical Trial Design Challenges

The clinical assessment of nose-to-brain formulations needs a study design to prove safety and therapeutic effectiveness. The clinical assessment must look at factors such as dose choice the target patient group, the delivery method, the length of treatment and major clinical endpoints. It may also be essential to separate the effects of CNS administration from those that come from systemic drug absorption. Structured clinical studies are vital, for deciding the clinical importance of preclinical results.[26][36]

9.7 Manufacturing and Scale-Up Challenges

Moving from lab-scale production to manufacturing of a nanocarrier formulation can change important features like particle size how much drug is trapped inside how the drug is released and how stable the product stays. These changes happen because the way things are made on a scale is different from the way they are made in a small lab. Because of this it's necessary to set up manufacturing methods. These methods must keep the product quality the same each time. Make sure the results are consistent across batches. To achieve this strong process controls must be in place. There also needs to be a quality standard that can be followed. Good Manufacturing Practices or GMP must be strictly followed. These practices help make sure that the product is safe, effective and meets all the rules needed for approval, by agencies.[34][35]

10 REGULATORY GAPS AND FUTURE PERSPECTIVES

10.1 Need For Harmonized Regulatory guidelines

Nose-to-brain drug delivery methods are advanced. They face challenges. The reason is that clear guidelines for measuring drug transport to the nervous system are still being developed. Current guidelines for products focus on quality and performance. However more evidence may be needed to confirm brain targeting, safety and treatment effectiveness. Better alignment of characterization methods, quality standards and clinical evaluation criteria could lead to regulatory assessments, around the world.[36]

10.2 Standardized characterization method

Standardized methods for characterizing products are important for checking how good and how well they work. Important things include the size of the particles how big they're what charge they have on the surface how much medicine they can hold how quickly the medicine comes out how much ends up in the nose and if the dose is the same every time. Using tests that have been proved to work and can be done the way every time helps scientists compare different versions more reliably and get the same results, for the people who need to approve the products.[24][36]

10.3 Standardized nose -to-brain transport model

Reliable in-vitro ex-vivo and in-vivo models are required to investigate how drugs move from the cavity to the brain. In-vitro models let us evaluate nasal permeability and the characteristics of formulations whereas animal models give us clues about how the drug spreads and how biology reacts. However differences, between models can affect how we interpret results. Applying protocols and choosing the right models can improve reproducibility and help move preclinical discoveries into clinical research.[37]

10.4 Improve predicative pre - clinical model

Better predictive preclinical models are essential to evaluate the safety and effectiveness of nose-to-brain formulations before clinical trials. Predictive preclinical models must account for variations in nasal structure the size of the olfactory region, mucociliary clearance and airflow between animals and humans which can change how drugs are deposited and absorbed. Combining experimental models with computational methods could improve the analysis of drug distribution data and help identify promising nose-, to-brain formulations for further development.[27][37]

10.5 Long term safety data base

Information on long-term safety is essential when we look at nose-to-brain formulations that are meant for regular use. Long-term safety concerns include nasal discomfort, changes in activity damage, to olfactory tissues and the risk that nanomaterials might accumulate in body tissues. More toxicology studies and a systematic collection of safety data help us spot late-onset problems and support decisions that rely on evidence. How testing we need depends on the nose-to-brain formulation, the active ingredient and how long it will be used.[38]

10.6 Regulatory Pathways for Nanotechnology-Based Nasal Products

Nasal products that use nanotechnology might need a check of how well they’re made the traits of the nanomaterials used how safe they are, how well they work and whether they follow manufacturing rules. The Guidelines for Evaluation

of Nano pharmaceuticals in India set up a system to look at the quality, safety and effectiveness of products. The right regulatory path for a nose-, to-brain formulation depends on what it's made of what it's meant to do and which product group it falls into. Talking to the regulatory body early can help figure out the exact rules that apply to your product.[39][40]

10.7 Integration of Advanced Analytical Tools

Using analytical and computer methods can make it easier to judge how well nose-to-brain drug delivery systems work. Techniques, like imaging measuring drugs in the body modeling and proven pharmacokinetic tests can help us look at where the drug lands in the nose how it spreads and which paths it takes to reach the brain. By putting all these tools we can get a clearer picture of how good a formulation is and help scientists spot limits before moving to human trials. Still each method must be tested carefully for the job it is meant to do.[24]

10.8 Need for Global Regulatory Collaboration

Working together between groups, academic researchers and drug companies is key to moving forward with nose-to-brain drug delivery. Sharing evidence building standard ways to test and describe the drugs and matching up how we test them in humans can cut down on wasted work. It also helps make results from studies easier to compare. When countries work together they can find gaps, in rules and help create clearer more consistent ways to test new nasal nanomedicines. This kind of teamwork makes the whole process smoother and more reliable. [36]

11 FUTURE REGULATORY NEEDS

The advancement of regulations is crucial for implementing nose-to-brain drug delivery systems in medical applications. Conventional nasal medications have established regulations. Specific guidelines for drugs that target the brain are still evolving. Updated regulations should emphasize protocols, testing methods, improved animal research, extended safety assessments and conclusive evidence that the drug effectively penetrates the brain. Regulators ought to promote science-led product development, thorough risk assessments and uniform quality assurance, for medications that use particles. These measures can enhance the safety, quality, effectiveness and reliability of medicines as they move from the laboratory to patients.[41] [42] [43]

12 CONCLUSION

From a perspective developing nose-to-brain systems requires thorough evidence of quality, safety and efficacy. Accurate analytical characterization, validated models, pharmacokinetic and pharmacodynamic evaluation, stability studies and robust Chemistry, Manufacturing and Controls (CMC) documentation are essential for product development.

Improved alignment of expectations, standardized testing protocols and cooperation between agencies could make the assessment and use of these intricate formulations better.

In conclusion sophisticated nose-to-brain drug delivery methods may bring benefits for CNS therapies; however, the successful use of nose-to-brain approaches in practice depends on solving scientific, formulation, safety, manufacturing and regulatory problems. Continuous research and defined science-based regulatory plans will be crucial, for creating effective and high-quality pharmaceutical products that target the nose and brain.

STATEMENTS ON COMPLIANCE WITH ETHICAL STANDARDS

Disclosure of conflict of interest

The authors declare no conflicts of interest regarding this manuscript.

REFERENCES

[1] Kundap UP, Bhuvanendran S, Kumari Y, Othman I, Shaikh MF. Plant derived phytocompound, embelin in CNS disorders: a systematic review. Front Pharmacol. 2017;8:76. doi:10.3389/fphar.2017.00076.

[2] Raghav M, Gupta V, Awasthi R, Singh A, Kulkarni GT. Nose-to-brain drug delivery: challenges and progress towards brain targeting in the treatment of neurological disorders. J Drug Deliv Sci Technol. 2023;86:104756. doi:10.1016/j.jddst.2023.104756.

[3] Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, Tian XQ. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine. 2014;9:2241-2257. doi:10.2147/IJN.S61288.

[4] Wu D, Chen Q, Chen X, Tang F, Chen J, Wang Y, et al. The blood-brain barrier: structure, regulation and drug delivery. Signal Transduct Target Ther. 2023;8:247. doi:10.1038/s41392-023-01481-w.

[5] Nance E, Pun SH, Saigal R, Sellers DL. Drug delivery to the central nervous system. Nat Rev Mater. 2022;7(4):314-331. doi:10.1038/s41578-021-00394-w.

[6] Ternovii JT, Quirpe PC, Khan F, Novack V. Non-invasive strategies for nose-to-brain drug delivery. J Clin Trials. 2020;10(7):439. [Verify the article title, authors, and publication details.]

[7] Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicological challenges during drug development. Drug Deliv Transl Res. 2022;12(4):735-757. doi:10.1007/s13346-020-00891-5.

[8] Agrawal M, Saraf S, Saraf S, et al. Neurotransmitters—key factors in neurological and neurodegenerative disorders of the central nervous system. Int J Mol Sci. 2022;23(11):5954. doi:10.3390/ijms23115954.

[9] GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344-381. doi:10.1016/S1474-4422(24)00038-3.

[10] Nance E, Pun SH, Saigal R, Sellers DL. Drug delivery to the central nervous system. Nat Rev Mater. 2022;7(4):314-331. doi:10.1038/s41578-021-00394-w. [Duplicate of reference 5; remove one entry.]

[11] Ronaldson PT, Davis TP. Blood-brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics. Expert Opin Drug Deliv. 2024;21(1):71-89. doi:10.1080/17425247.2024.2306138.

[12] Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614-628. doi:10.1016/j.addr.2011.11.002.

[13] Drath I, Richter F, Feja M. Nose-to-brain drug delivery: from bench to bedside. Transl Neurodegener. 2025;14:23. doi:10.1186/s40035-025-00481-w.

[14] Huang Q, Chen X, Yu S, Gong G, Shu H. Research progress in brain-targeted nasal drug delivery. Front Aging Neurosci. 2024;15:1341295. doi:10.3389/fnagi.2023.1341295.

[15] Safarov R, Fedotova O, Uvarova A, Gordienko M, Menshutina N. Review of intranasal active pharmaceutical ingredient delivery systems. Pharmaceuticals (Basel). 2024;17(9):1180. doi:10.3390/ph17091180.

[16] Papakyriakopoulou P, Valsami G. The nasal route for nose-to-brain drug delivery: advanced nasal formulations for CNS disorders. Expert Opin Drug Deliv. 2025;22(6):823-839. doi:10.1080/17425247.2025.2489553.

[17] Nguyen TTL, Duong VA. Advancements in nanocarrier systems for nose-to-brain drug delivery. Pharmaceuticals (Basel). 2025;18(5):615. doi:10.3390/ph18050615.

[18] Bonferoni MC, Rossi S, Sandri G, Ferrari F. Nanoemulsions for nose-to-brain drug delivery. Pharmaceutics. 2019;11(2):84. doi:10.3390/pharmaceutics11020084.

[19] Nguyen TTL, Duong VA. Advancements in nanocarrier systems for nose-to-brain drug delivery. Pharmaceuticals (Basel). 2025;18(5):615. doi:10.3390/ph18050615. [Duplicate of reference 17; remove one entry.]

[20] Zhang Y, Zou Z, Liu S, Miao S, Liu H. Nanogels as novel nanocarrier systems for efficient delivery of CNS therapeutics. Front Bioeng Biotechnol. 2022;10:954470. doi:10.3389/fbioe.2022.954470.

[21] Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig. 2023;53(1):119-152. doi:10.1007/s40005-022-00589-5.

[22] Bonaccorso A, Ortis A, Musumeci T, Carbone C, Hussain M, Di Salvatore V, et al. Nose-to-brain drug delivery and physico-chemical properties of nanosystems: analysis and correlation studies of data from scientific literature. Int J Nanomedicine. 2024;19:5619-5636. doi:10.2147/IJN.S452316.

[23] Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig. 2023;53(1):119-152. doi:10.1007/s40005-022-00589-5. [Duplicate of reference 21; remove one entry.]

[24] Wong CYJ, Baldelli A, Tietz O, van der Hoven J, Suman J, Ong HX, et al. An overview of in vitro and in vivo techniques for characterization of intranasal protein and peptide formulations for brain targeting. Int J Pharm. 2024;654:123922. doi:10.1016/j.ijpharm.2024.123922.

[25] Boyuklieva R, Zagorchev P, Pilicheva B. Computational, in vitro, and in vivo models for nose-to-brain drug delivery studies. Biomedicines. 2023;11(8):2198. doi:10.3390/biomedicines11082198.

[26] Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicological challenges during drug development. Drug Deliv Transl Res. 2022;12(4):735-757. doi:10.1007/s13346-020-00891-5. [Duplicate of reference 7; remove one entry.]

[27] Yokel RA. Direct nose to the brain nanomedicine delivery presents a formidable challenge. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022;14(2). doi:10.1002/wnan.1767.

[28] Đorđević S, Medel Gonzalez M, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500-525. doi:10.1007/s13346-021-01024-2.

[29] Papakyriakopoulou P, Valsami G. The nasal route for nose-to-brain drug delivery: advanced nasal formulations for CNS disorders. Expert Opin Drug Deliv. 2025;22(6):823-839. doi:10.1080/17425247.2025.2489553. [Duplicate of reference 16; remove one entry.]

[30] Lofts A, Abu-Hijleh F, Rigg N, Mishra RK, Hoare T. Using the intranasal route to administer drugs to treat neurological and psychiatric illnesses: rationale, successes, and future needs. CNS Drugs. 2022;36(7):739-770. doi:10.1007/s40263-022-00930-4.

[31] Central Drugs Standard Control Organisation (CDSCO). Official website [Internet]. Available from: https://cdsco.gov.in/

[32] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH guidelines [Internet]. [cited 2026 Oct 27]. Available from: https://www.ich.org/page/search-index-ich-guidelines

[33] Wu X, Zang R, Qiu Y, Zhang Y, Peng J, Cheng Z, et al. Intranasal drug delivery technology in the treatment of central nervous system diseases: challenges, advances, and future research directions. Pharmaceutics. 2025;17(6):775. doi:10.3390/pharmaceutics17060775.

[34] US Food and Drug Administration (FDA). Nasal spray and inhalation solution, suspension, and spray drug products—chemistry, manufacturing, and controls documentation: guidance for industry [Internet]. Silver Spring (MD): FDA; 2002 Jul. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nasal-spray-and-inhalation-solution-suspension-and-spray-drug-products-chemistry-manufacturing-and

[35] US Food and Drug Administration (FDA). Drug products, including biological products, that contain nanomaterials: guidance for industry [Internet]. Silver Spring (MD): FDA; 2022 Apr. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry

[36] Zhang X, Chow S, Chan HW, Chow SF. Overcoming translational barriers in nose-to-brain drug delivery for clinical applications. J Pharm Sci. 2026;115(2):104156. doi:10.1016/j.xphs.2026.104156.

[37] Haasbroek-Pheiffer A, Van Niekerk S, Van der Kooy F, et al. In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose-to-brain drug delivery. Biopharm Drug Dispos. 2023;44(1):94-112. [DOI not provided; verify bibliographic details.]

[38] Gao T, Chu Q, Xing X, Liu Y, Fu S, Liu D. Intranasal nano-delivery systems: emerging strategies for central nervous system disease therapeutics. Int J Nanomedicine. 2026;21:588836. doi:10.2147/IJN.S588836.

[39] Department of Biotechnology, Government of India; Indian Council of Medical Research; Central Drugs Standard Control Organization. Guidelines for evaluation of nanopharmaceuticals in India. New Delhi: Government of India; 2019.

[40] Medicines and Healthcare products Regulatory Agency (MHRA). Decision tree for navigating nanotechnology-based products for medical application. United Kingdom: MHRA; 2025. [Verify the official title and publication details.]

[41] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q8(R2): pharmaceutical development [Internet]. Available from: https://www.ich.org/page/quality-guidelines

[42] Dsouza AA, Kahan M, Yang A, et al. Formulation considerations in enhancing olfactory mucosal deposition for nose-to-brain drug delivery. Drug Deliv Transl Res. 2026;16:2552-2577. doi:10.1007/s13346-026-02097-7.

[43] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q8(R2): pharmaceutical development; ICH Q9(R1): quality risk management; ICH Q10: pharmaceutical quality system [Internet]. Available from: https://www.ich.org/page/quality-guidelines